

RYVU THERAPEUTICS S.A.
Q3 2026 Report

TABLE OF CONTENTS

1. ECONOMIC AND FINANCIAL HIGHLIGHTS 2

1.1. Financial Results Obtained in the Reporting Period 2

1.2. Management Board comments to the financial results 4

1.3. The Company's Assets and the Structure of Assets and Liabilities 6

1.4. Current and Projected Financial Condition 6

2. MANAGEMENT BOARD INFORMATION ON ACTIVITIES 8

2.1. The Pipeline 8

2.2. Significant events in Q1-Q3 2026 13

2.3. Unusual events occurring in the reporting period 24

3. THE ISSUER'S CORPORATE BODIES 25

4. INFORMATION ON THE SHAREHOLDERS HOLDING (DIRECTLY OR INDIRECTLY) AT LEAST 5% OF THE TOTAL NUMBER OF VOTES AT THE GENERAL SHAREHOLDERS' MEETING OF THE COMPANY AND ON SHARES HELD BY MEMBERS OF THE ISSUER'S MANAGEMENT BOARD AND SUPERVISORY BOARD 26

5. STATEMENT OF THE MANAGEMENT BOARD REGARDING APPLICABLE ACCOUNTING PRINCIPLES. 28

6. ADDITIONAL INFORMATION 29

1. ECONOMIC AND FINANCIAL HIGHLIGHTS

1.1. Financial Results Obtained in the Reporting Period

Condensed Interim Financial Statements of Ryvu Therapeutics S.A. ("Company", "Issuer", "Ryvu") for the period from January 1, 2026, to September 30, 2026 are prepared in accordance with the requirements of the International Accounting Standard No. 34 "Interim Financial Reporting" endorsed by the EU ("IAS 34").

Selected data of the statement of financial position are as follows:

Ryvu Therapeutics S.A.	Data in PLN thousand		Data in EUR thousand	
Item	**30.09.2026**	31.12.2025	**30.09.2026**	31.12.2025
Total assets	**174,399**	224,436	**39,934**	53,100
Short-term receivables	**29,844**	20,100	**6,834**	4,756
Cash and cash equivalents	**38,486**	59,606	**8,813**	14,102
Other current and non-current financial assets	**19,067**	48,072	**4,366**	11,373
Total liabilities	**165,028**	170,601	**37,788**	40,363
Long-term liabilities	**109,733**	109,020	**25,127**	25,793
Short-term liabilities	**55,296**	61,581	**12,662**	14,569
Total equity	**9,371**	53,834	**2,146**	12,737
Share capital	**9,248**	9,248	**2,118**	2,188

Selected data of statement of comprehensive income are as follows:

Ryvu Therapeutics S.A.	Data in PLN thousand				Data in EUR thousand			
Item	**From 01.01.2026 to 30.09.2026**	From 01.01.2025 to 30.09.2025	**From 01.07.2026 to 30.09.2026**	From 01.07.2025 to 30.09.2025	**From 01.01.2026 to 30.09.2026**	From 01.01.2025 to 30.09.2025	**From 01.07.2026 to 30.09.2026**	From 01.07.2025 to 30.09.2025
Revenues from sales	**35,400**	34,357	**12,903**	11,445	**8,271**	8,110	**2,976**	2,682
Revenues from subsidies	**14,354**	17,667	**4,630**	4,577	**3,354**	4,170	**1,068**	1,072
Revenues from R&D projects	**9,370**	9,897	**2,928**	3,473	**2,189**	2,336	**675**	814
Other operating revenues	**4**	11	**4**	6	**1**	3	**1**	1
Revenues from operating activities	**59,128**	61,932	**20,465**	19,500	**13,815**	14,619	**4,720**	4,569
Operating expenses	**-102,923**	-152,691	**-35,412**	-44,896	**-24,048**	-36,042	**-8,168**	-10,519
Operating expenses without Incentive Scheme and valuation of Rezera (NodThera) shares	**-98,716**	-139,777	**-31,156**	-44,235	**-23,065**	-32,994	**-7,186**	-10,365
Depreciation	**-5,962**	-7,576	**-1,816**	-2,858	**-1,393**	-1,788	**-419**	-670
Valuation of Incentive Scheme	**-298**	-2,570	**-54**	-687	**-70**	-607	**-12**	-161
Loss from operating activities (EBIT)	**-43,795**	-90,760	**-14,946**	-25,396	**-10,233**	-21,423	**-3,447**	-5,950
Loss from operating activities (EBIT) without Incentive Scheme and valuation of Rezera (NodThera) shares	**-39,588**	-77,845	**-10,691**	-24,735	**-9,250**	-18,375	**-2,466**	-5,796
Loss before income tax	**-44,369**	-83,623	**-19,000**	-24,707	**-10,367**	-19,739	**-4,382**	-5,789
Net loss	**-44,762**	-83,640	**-19,057**	-24,707	**-10,458**	-19,743	**-4,396**	-5,789
Net loss without Incentive Scheme	**-44,464**	-81,071	**-19,003**	-24,019	**-10,389**	-19,136	**-4,383**	-5,628
EBITDA	**-37,832**	-83,184	**-13,130**	-22,538	**-8,839**	-19,635	**-3,029**	-5,281
EBITDA without Incentive Scheme and valuation of Rezera (NodThera) shares	**-33,626**	-70,269	**-8,875**	-21,877	**-7,857**	-16,587	**-2,047**	-5,126
Net cash flows from operating activities	**-49,020**	-86,008	**-16,554**	-17,417	**-11,453**	-20,302	**-3,818**	-4,081
Net cash flows from investing activities	**31,294**	18,172	**5,259**	-13	**7,312**	4,289	**1,213**	-3
Net cash flows from financing activities	**-3,078**	-2,784	**-782**	-614	**-719**	-657	**-180**	-144
Total net cash flow	**-20,804**	-70,620	**-12,077**	-18,044	**-4,861**	-16,669	**-2,786**	-4,228
Number of shares (weighted average)	**23,120,148**	23,120,148	**23,120,148**	23,120,148	**23,120,148**	23,120,148	**23,120,148**	23,120,148
Profit (loss) per share (in PLN)	**-1.94**	-3.62	**-0.82**	-1.07	**-0.45**	-0.85	**-0.19**	-0.25
Diluted profit (loss) per share (in PLN)	**-1.94**	-3.62	**-0.82**	-1.07	**-0.45**	-0.85	**-0.19**	-0.25
Book value per share (in PLN)	**0.41**	3.08	**0.41**	3.08	**0.09**	0.72	**0.09**	0.72
Diluted book value per share (in PLN)	**0.41**	3.08	**0.41**	3.08	**0.09**	0.72	**0.09**	0.72

Selected financial data presented in the quarterly report were converted to Euro as follows:

1. Items relating to the profit and loss statement and the cash flow statement were converted using the exchange rate constituting the arithmetic average of the exchange rates, applicable as of the last day of every month in the given period, based on the information published by the National Bank of Poland (NBP):
   - for the period from 01/01/2026 – 30/09/2026: PLN 4.2800;
   - for the period from 01/01/2025 – 30/09/2025: PLN 4.2365;

2. Balance sheet items were converted using the average exchange rate announced by the NBP applicable as of the balance sheet date; which were:
   - as of 30 September 2026: PLN 4.3672;
   - as of 31 December 2025: PLN 4.2267.

1.2. Management Board comments to the financial results

In the first three quarters of 2026, Ryvu Therapeutics S.A. recognized total operating revenue of PLN 59,128 thousand, which constitutes a decrease compared to the corresponding period in 2025, when total operating revenue amounted to PLN 61,932 thousand. This results from a decrease in revenues from subsidies (a decrease of PLN 3,313 thousand) and a decrease in revenues from R&D projects (a decrease of PLN 527 thousand), partially compensated by an increase in revenues from sales (an increase of PLN 1,043 thousand) compared to the corresponding period in 2025.

In the first nine months of 2026, Ryvu reported a net loss, as well as an operating loss. The net and operating losses result from the fact that the Company focuses on increasing the value of the ongoing projects that will be commercialized at a later stage of development.

The Company's net loss for the period ended September 30, 2026, amounted to PLN 44,762 thousand and was lower compared to the net loss of PLN 83,640 thousand in the corresponding period of 2025. The Company's operating loss without Incentive Scheme and valuation of Rezera (NodThera) shares in the first three quarters of 2026 decreased by PLN 38,257 thousand compared to the corresponding period of 2025, from PLN 77,845 thousand in the first three quarters of 2025 to PLN 39,588 thousand in the first three quarters of 2026. Operating costs without Incentive Scheme and valuation of Rezera (NodThera) shares decreased from PLN 139,777 thousand in the first three quarters of 2025 to PLN 98,716 thousand in the first three quarters of 2026. The net result for the first three quarters of 2026 was also affected by the negative valuation of Rezera shares (PLN 3,909 thousand, compared to a negative impact of PLN 10,345 thousand in the corresponding period of 2025).

In Q3 2026, the Company's net loss decreased by 23% year on year, from PLN 24,707 thousand to PLN 19,057 thousand, and operating costs without Incentive Scheme and valuation of Rezera (NodThera) shares decreased from PLN 44,235 thousand to PLN 31,156 thousand, primarily reflecting lower expenditure on research and clinical development programs following the strategic prioritization of the portfolio.

The reduction in operating costs reflects a deliberate concentration of resources on the programs with the highest near-term value-creation potential, principally the RIVER-81 Phase II study of romaciclib in relapsed/refractory AML following venetoclax-based therapy failure — a setting with no approved therapeutic option and a median overall survival of under three months. This focus is expected to accelerate the generation of clinical evidence required to conclude a partnering agreement and to support further program development. Furthermore, the Company continues to maintain cost discipline following the strategic reorganization announced in February 2025.

Valuation of shares in Rezera Inc. (formerly NodThera Inc.)

Effective September 9, 2026, NodThera Inc. changed its name to Rezera Inc. The Company holds shares in Rezera Inc. (formerly NodThera Inc.), a biotechnology company developing NLRP3 inhibitors for the treatment of inflammatory and neuroinflammatory diseases.

On July 15, 2026, Rezera Inc. issued Series D4 Preferred Stock. The offering comprised 16,389,452 shares at a price of USD 0.9259 per share. As a result, Rezera received total financing of USD 15,174,993.66. The offering was made exclusively to existing investors. Series D shares carry the same preferential rights as Series A, B, and C shares. Ryvu did not participate in this financing round.

On October 21, 2026, Rezera Inc. filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) in connection with its planned initial public offering on Nasdaq. In the amended prospectus (Form S-1/A dated November 9, 2026), Rezera Inc. set an indicative price range of USD 11–13 per share and disclosed a 1-for-35.722 reverse stock split effected on November 4, 2026. As of the date of this report, the offering has not been priced or completed, and there can be no assurance that it will be completed, or as to its timing or final terms.

Ryvu holds 1,910,000 shares of Junior Preferred Stock of Rezera Inc., which will be converted into 53,468 shares of common stock upon completion of the offering. As of December 31, 2025, Ryvu held a 1.2% stake in Rezera. Following the Series D4 issuance, Ryvu's shareholding decreased to 1.06% on a fully diluted basis (1.29% of issued shares as of September 30, 2026).

The price range indicated in the prospectus constitutes the most recent information on the price of Rezera Inc. shares available as of the date of preparation of the financial statements. The Management Board considered the midpoint of this range to best reflect the fair value of the shares held as of the balance sheet date. Accordingly, the valuation was based on a share price of USD 0.3359 per share (the midpoint of the price range, i.e. USD 12, divided by the reverse split ratio of 35.722).

As of September 30, 2026, the total valuation of Ryvu's stake amounts to PLN 2,467 thousand (based on the NBP's average exchange rate of 3.8449 PLN/USD as of September 30, 2026), which represents a decrease in valuation of PLN 3,909 thousand compared to December 31, 2025.

Financing from the European Investment Bank

On August 16, 2022, the Company concluded a financing agreement with the European Investment Bank ("EIB"). Under the agreement, the EIB agreed to grant the Company a loan in the maximum amount of EUR 22,000,000.

The financing was paid in three tranches. The Company is obliged to repay each of the paid tranches in one installment in 2029, 5 years after its launch.

In consideration for the financing received, the Company issued to the EIB subscription warrants representing in aggregate 2.5% of the Company's fully issued share capital. The Company undertook to issue 592,825 subscription warrants to the EIB.

Additionally, the put option issued by the Company creates a contractual obligation to repurchase its equity instruments (warrants). As of September 30, 2026, Ryvu recognized a positive impact of the put option in the amount of PLN 6,221 thousand.

1.3. The Company's Assets and the Structure of Assets and Liabilities

As of September 30, 2026, the value of the Company's assets was PLN 174,399 thousand and decreased by PLN 50,037 thousand compared to the end of 2025 (PLN 224,436 thousand), mainly due to expenditures incurred on discovery and clinical projects. Among current assets, the highest value was cash, which amounted to PLN 38,486 thousand (at the end of 2025, it was PLN 59,606 thousand), together with other financial assets of PLN 19,067 thousand (at the end of 2025, it was PLN 48,072 thousand). Non-current assets are mainly the Research and Development Centre for Innovative Drugs (named 'CBR') and laboratory equipment, as well as the valuation of Rezera shares of PLN 2,467 thousand.

Ryvu's equity amounted to PLN 9,371 thousand as of September 30, 2026, and decreased by PLN 44,463 thousand compared to December 31, 2025. The decrease in equity is attributable to the net loss recorded for the period. The other source of asset funding is long-term liabilities, which amounted to PLN 109,733 thousand at the end of September 2026. The long-term liabilities are mainly related to the loan received from the European Investment Bank. Additionally, long-term liabilities include deferred income, largely related to deferred revenue from the BioNTech agreement and the infrastructure subsidy for CBR.

The asset structure demonstrates the Company's financial liquidity, which is confirmed by the following ratios:

	30.09.2026	31.12.2025
Current ratio current assets/current liabilities including short-term provisions and accruals (excl. deferred revenues)	1.82	2.45
Quick ratio (current assets-inventory)/current liabilities including short-term provisions and accruals (excl. deferred revenues)	1.79	2.43

Cash surpluses not used in operating activities are deposited in low-risk financial instruments like bank deposits and investment funds.

1.4. Current and Projected Financial Condition

The Company maintains adequate liquidity to fund its planned operations, supported by its current cash position and the financing received from the European Investment Bank. The Company continues to evaluate additional non-dilutive financing options to support the clinical development of romaciclib and other pipeline programs.

As of September 30, 2026, the value of the Company's cash and other financial assets amounted to PLN 57,553 thousand (PLN 38,486 thousand in cash at the banks, PLN 19,067 thousand in investment funds), and as of November 13, 2026, it was PLN 61,598 thousand (PLN 48,943 thousand in cash at the banks and PLN 12,655 thousand in investment funds). The increase in cash resulted from receipt of payment for a significant invoice after the reporting date.

Ryvu continues to advance three key strategic collaborations, under which all incurred costs are fully reimbursed, and the Company remains eligible to receive multiple financial milestones: Menarini, relating to JASPIS-01; BioNTech, relating to discovery programs; and Exelixis, relating to STING-agonist-based ADCs.

These partnerships are important because they provide validation of Ryvu's scientific platform, reduce internal funding requirements, and create the potential for milestone-driven upside.

In parallel, Ryvu continues to engage with potential partners for its fully owned programs.

Ryvu is also continuing to build Keelira, its dedicated early clinical development services business launched in August 2026 (described in more detail below), which commercializes clinical development capabilities developed on Ryvu's own oncology pipeline and already applied in external clinical collaborations. The Company expects Keelira to generate a growing, capital-efficient complementary revenue stream as its client portfolio expands, alongside Ryvu's own oncology pipeline, which remains its strategic priority.

Cash inflow from previous share issues, funds obtained from EU subsidies, financing received from the EIB, funds supporting R&D projects, and cash generated from the commercialization of projects enable the Company to execute its planned investments, particularly the development of ongoing and new innovative projects and the expansion of laboratory infrastructure. The Company's future revenues will strongly depend on the ability to commercialize its R&D projects.

The Company may obtain additional non-dilutive financing from multiple sources, among others:

- potential strategic and financial partners,
- financial milestones and research funding from current collaborations,
- new projects with current and new partners, including new clients of Keelira, the Company's clinical services business.

2. MANAGEMENT BOARD INFORMATION ON ACTIVITIES

2.1. The Pipeline

Ryvu Therapeutics is advancing a broad pipeline addressing emerging targets in oncology.

Ryvu's pipeline includes candidates with differentiated therapeutic mechanisms, including programs directed at kinases, synthetic lethality, immuno-oncology and immunometabolism pathways. These research and development projects are represented below.



Source: Company's own data.

Romaciclib (RVU120)

Romaciclib (RVU120) is a clinical-stage, selective, first-in-class dual inhibitor of CDK8 and CDK19 kinases. The international nonproprietary name of romaciclib was assigned to RVU120 by the WHO and announced on the proposed list in February 2025, followed by the publication of the INN Recommended List 94 on November 3, 2025. Romaciclib has demonstrated efficacy in several solid tumors and hematologic malignancies in *in vitro* and *in vivo* models. CDK8 and its paralog, CDK19, are kinase submodules of the mediator complex, involved in both transcriptional activation and repression, playing central roles in maintaining the viability of cancer cells and their undifferentiated state across various tumor types (Dannappel et al., 2019; Rzymski et al., 2015; Philip et al., 2018). CDK8/19 mediator complex integrates basal transcriptional machinery with the activity of oncogenic transcriptional and epigenetic factors. Inhibition of CDK8/19 can repress key oncogenic transcriptional programs and induce lineage commitment genes in acute myeloid leukemia (AML).

Romaciclib has been internally discovered by Ryvu and has received support from the Leukemia & Lymphoma Society Therapy Acceleration Program® (TAP; the organization has operated as Blood Cancer United since August 2025), a strategic initiative to partner directly with innovative

biotechnology companies and leading research institutions to accelerate the development of promising new therapies for blood cancers.

On March 25, 2020, the U.S. Food and Drug Administration (FDA) granted romaciclib an orphan drug designation (ODD) for the treatment of patients with AML.

Based on the available translational and clinical data, Ryvu is executing a Clinical Development Plan (CDP) for romaciclib with focus on hematologic malignancies.

Five clinical studies with romaciclib have ended enrollment and all patients have discontinued study treatment: (i) Phase Ib in patients with AML/HR-MDS (NCT04021368; CLI120-001, RIVER-51), (ii) Phase I/II in patients with relapsed/refractory metastatic or advanced solid tumors (NCT05052255; RVU120-SOL-021, AMNYS-51), (iii) Phase II in patients with AML/HR-MDS (NCT06268574; RIVER-52), (iv) Phase II in patients with intermediate or high-risk, primary or secondary myelofibrosis (NCT06397313, POTAMI-61), (v) Phase II in patients with lower risk myelodysplastic neoplasms (NCT06243458, REMARK).

Three clinical trials involving romaciclib are currently active: RIVER-81, enrolling patients; ROVER-01, continuing treatment of patients rolled over from the POTAMI-61 and REMARK studies; and the MEDWAY study, launched in August 2026 but not yet recruiting.

RIVER-81 Phase II study

On January 31, 2024, Ryvu announced the dosing of the first patient in the RIVER-81 Phase II study of romaciclib in combination with venetoclax (NCT06191263). RIVER-81 is a multicenter, open-label clinical trial that aims to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of romaciclib when administered in combination with venetoclax to patients with AML who are relapsed or refractory to prior therapy with venetoclax and a hypomethylating agent.

As announced by the Company on November 4, 2026, updated preliminary results from RIVER-81 will be presented at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans, USA, on December 12-15, 2026. The abstract summarized results from 58 patients treated as of the July 1, 2026, data cut-off. The combination showed antileukemic activity across a range of genotypes, including high-risk mutations: nine patients achieved CR, CRh, or CRi, and two additional patients achieved partial remission. Safety findings supported 150 mg once daily as a tolerable starting dose, with adaptive escalation to 200 mg once daily for eligible non-responders.

Ryvu initiated an expansion cohort in the RIVER-81 trial, comprising approximately 30 patients with relapsed or refractory AML, to confirm the positive efficacy demonstrated in the 150 mg once-daily dose cohort of romaciclib in combination with 400 mg once-daily venetoclax. In Europe, the updated RIVER-81 protocol, reflecting feedback received during the FDA meeting, has been approved through CTIS, with approval granted on July 31, 2026, enabling initiation of the expansion cohort in European countries. Following this approval, the first patient in the new cohort was dosed on August 26, 2026. The study continues to enroll patients in Part 2.

The execution of the RIVER-81 study is supported by a PLN 62.3 million grant from the Polish Medical Research Agency (ABM).

ROVER-01 study

Patients from the POTAMI-61 and REMARK studies, which have ended enrollment, were transferred into the ROVER-01 rollover study. These patients will continue to receive treatment with romaciclib as long as they benefit from romaciclib according to investigators' assessment.

MEDWAY Phase I study

Additionally, an investigator-initiated Phase I study to evaluate romaciclib in combination with everolimus in pediatric patients with medulloblastoma (MEDWAY) was announced in September 2025. The MEDWAY project will be executed by the Children's Memorial Health Institute (IPCZD) as a sponsor of the study under an approx. PLN 40 million grant awarded by the Polish Medical Research Agency. The study was launched in August 2026. Romaciclib's development in a pediatric indication may qualify for a Rare Pediatric Disease Priority Review Voucher (PRV) or other incentive from the U.S. Food and Drug Administration upon regulatory approval.

Dapolsertib (MEN1703, SEL24)

Dapolsertib (also known as MEN1703 or SEL24) is a selective, small-molecule dual inhibitor of PIM and FLT3 kinases, two enzymes strongly implicated in the malignant transformation of hematopoietic cells and lymphomagenesis. The compound was discovered by Ryvu and is currently in clinical development in collaboration with Menarini Group as a therapeutic option for various cancers. The licensing agreement with Menarini was executed in March 2017. Initially, dapolsertib was developed as a potential treatment for patients with relapsed/refractory acute myeloid leukemia (AML). More details of the completed Phase I/II clinical study are available at ClinicalTrials.gov under the identifier NCT03008187. Data from this part of the study were presented at multiple scientific conferences and symposia. Ryvu has been supporting this project with translational research.

Based on a decision announced in September 2023, Menarini has continued the development of dapolsertib by initiating a new Phase II study in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) – JASPIS-01 study. Menarini fully funds all study activities, while Ryvu acts as the operational partner to execute the JASPIS-01 study on behalf of Menarini. The licensing partnership with Menarini, including the total milestones and royalties due to Ryvu upon the achievement of certain events, remains unchanged.

The JASPIS-01 study is an open-label, Phase II clinical trial investigating dapolsertib as a monotherapy and in combination with glofitamab for patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). It comprises three parts: Part 1 focuses on evaluating safety and preliminary anti-lymphoma activity in approximately 18 patients; Part 2, based on Part 1 results, will assess anti-tumor activity as a primary objective in a larger group of patients, as well as safety and tolerability; and Part 3 will offer an optional randomized comparison.

The JASPIS-01 study was initiated in Q4 2024. On March 26, 2025, the first patient was dosed. The study was initiated at clinical sites in Poland. It is also currently recruiting in France, Spain, and the United Kingdom. The study is registered on ClinicalTrials.gov under NCT06534437.

On November 4, 2026, the Menarini Group and Ryvu Therapeutics announced that the first clinical data from the ongoing Phase II JASPIS-01 study of dapolsertib will be presented as a poster at the 68th American Society of Hematology (ASH) Annual Meeting in New Orleans on December 13, 2026. The abstract covers 15 patients from Group 2, who received dapolsertib monotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL) after exhausting standard

treatment options. These patients had a median of four prior lines of therapy, including CAR-T cell therapy (53%) and CD3×CD20 bispecific antibodies (60%). Clinical benefit was seen in 4 of 15 patients, including one complete response lasting nearly 12 months and still ongoing at the data cutoff, and the safety profile was manageable. Enrollment in the study is ongoing.

On July 22, 2026, Ryvu concluded an amendment to its global license agreement with Menarini Group concerning the further clinical development of dapolsertib by initiating a new clinical study in patients with myelofibrosis (MF), a rare hematological malignancy, based on preclinical data indicating activity of dapolsertib in MF models. Ryvu acts as the study sponsor and will be responsible for the operational conduct of the study on behalf of Menarini Group, while Menarini will fund the activities covered by the amendment. This Phase II clinical study, SPHENE-01, will investigate dapolsertib primarily as monotherapy in patients with myelofibrosis. The study is expected to be conducted in Europe and initiated in Q1 2027.

BioNTech: Clinical collaboration

In September 2025, Ryvu concluded a strategic agreement with BioNTech to provide specialized services to accelerate site activation and patient enrollment for several of BioNTech's priority oncology clinical programs in Poland, covering indications such as lung, breast, and colorectal cancers. Under the agreement, both parties leverage Ryvu's operational excellence, extensive expertise in oncology clinical operations, and established trial site network to enhance and streamline access for Polish patients to BioNTech's investigational immunotherapies.

Preclinical and discovery stage projects

Synthetic lethality projects

RVU305 Oral, brain-penetrant, MTA-cooperative PRMT5 inhibitor in IND/CTA-enabling studies

RVU305 is a potentially best-in-class, oral, brain-penetrant, MTA-cooperative PRMT5 inhibitor, currently in the IND/CTA-enabling phase. It is designed to target cancers characterized by the deletion of the MTAP metabolic gene, a genetic alteration found in approximately 10–15% of all human tumors. RVU305 leverages this vulnerability as an MTA-cooperative PRMT5 inhibitor, selectively impeding the growth of cancer cells harboring MTAP deletions.

In H1 2026, RVU305 achieved key preclinical milestones, including completion of toxicology studies and API/IMP manufacturing. Non-clinical GLP-toxicology studies were completed in two species with a favorable safety profile and no major toxicology findings; these data will inform the calculation of the first-in-human (FIH) starting dose. In parallel, synthesis of a GMP batch as well as manufacturing of the final clinical-trial drug product were completed.

Stability studies for the clinical drug product are ongoing in accordance with the established stability program and applicable ICH guidelines. Data generated to date support the required quality attributes of the drug product under the tested storage conditions, while additional stability time points are being collected to further characterize its stability profile. Building on these results, Ryvu is currently preparing the documentation package required for the submission of a Clinical Trial Application (CTA) to the relevant regulatory authority, subject to securing a development partnership.

Novel Multi-Target Discovery

OMNI Prime – Novel Small Molecule Precision Oncology

In addition to its disclosed drug discovery programs, Ryvu continues to advance its OMNI Prime platform, focused on the discovery and validation of novel therapeutic targets for first-in-class precision oncology treatments. The platform's development is supported by grant-funded initiatives covering both common and rare cancers.

ONCO Prime and PERO

ONCO Prime focuses on identifying novel therapeutic vulnerabilities in major cancer indications, including colorectal cancer, lung adenocarcinoma, and triple-negative breast cancer (TNBC). During Q3 2026, Ryvu continued validating targets identified in previous CRISPR screens and expanded its discovery capabilities through the implementation of a more comprehensive genome-wide CRISPR library. Initial benchmarking demonstrated improved performance, supporting future screening activities in TNBC models. In parallel, the PERO program advanced the functional characterization of selected targets using an innovative base-editing tiling approach, identifying functional pockets with first-in-class potential to guide small-molecule inhibitor development.

PANACEA-NOVO

In September 2026, Ryvu secured approximately PLN 105.6 million in grant funding from the National Centre for Research and Development (NCBR) for PANACEA-NOVO, a project focused on developing an integrated technology platform for the discovery and validation of novel therapeutic targets in rare cancers. The project aims to establish a patient-oriented approach connecting cancer biology, target identification and validation, and the development of innovative targeted therapies, expanding Ryvu's discovery capabilities into areas of significant unmet medical need.

ADC – Novel ADC payloads

Ryvu continues to advance its next-generation small-molecule payload program for antibody-drug conjugates (ADCs). RVU602 payloads have a mechanism of action distinct from TOPO1 and tubulin inhibitors. They remain active in TOPO1 inhibitor-resistant models, are optimized against P-gp efflux and show additional immunomodulatory activity. Conjugation to four different antibodies (sacituzumab, trastuzumab, cetuximab and telisotuzumab) yielded stable, potent ADCs, confirming the payloads' plug-and-play potential. In the subsequent stage, in vivo antitumor activity was confirmed with 100% complete remissions achieved in a xenograft. Activity in patient-derived TNBC models further supported the payloads' clinical potential. Current activities focus on defining the safety window, a key step toward selecting a candidate for further preclinical development.

Progress of the program was recently presented at the DDE 2026 conference in Berlin and the ADC Symposium 2026 in Prague.

STING agonist ADC collaboration with Exelixis

In July 2022, Ryvu signed a licensing agreement with Exelixis to collaborate on novel targeted therapies based on the advanced STING agonist technology developed at Ryvu. To date, under the terms of the collaboration, Ryvu has received an upfront payment of USD 3 million and a total of USD 3 million in milestone payments from Exelixis. The partnership has developed highly potent STING-activating antibody-drug conjugates that demonstrate picomolar in vitro activity and antigen-specific activation of the STING pathway; further development of these compounds is currently ongoing; however, progress on the project remains confidential.

BioNTech: Multi-target research collaboration

In November 2022, BioNTech and Ryvu initiated a comprehensive, multi-target research collaboration to advance small-molecule programs focused on immune modulation in cancer and potentially other disease areas. Under this partnership, BioNTech has the right to acquire global development and commercialization rights for these programs. While multiple research initiatives are underway as part of this collaboration, detailed information about these programs remains confidential.

2.2. Significant events in Q1-Q3 2026

2.2.1. During the reporting period

Update on the Food and Drug Administration (FDA) Type C meeting regarding romaciclib (RVU120)

On January 16, 2026, the Company received the minutes of the Type C meeting with the U.S. Food and Drug Administration, which was held on January 13, 2026, regarding the component of the romaciclib (RVU120) development program related to its combination with venetoclax for the treatment of patients with relapsed or refractory acute myeloid leukemia (R/R AML) following failure of venetoclax in combination with a hypomethylating agent. This indication is currently being tested in the RIVER-81 study. The other indications in which romaciclib is being developed by Ryvu were not discussed at this meeting.

The purpose of the meeting, which was held at Ryvu's request, was to obtain the FDA's feedback on the further clinical development of romaciclib in patients with R/R AML in the United States, with respect to the observed benefit-risk profile. Ryvu also asked for guidance on dose optimization and design assumptions for future registrational clinical studies.

The FDA raised no objections to opening the expansion cohort in the United States with romaciclib at a dose of 150 mg once daily (QD) in combination with venetoclax, which was assessed in Cohort 4 of the RIVER-81 study.
At the same time, the FDA provided the Company with general guidance regarding:

- expectations related to dose optimization based on an integrated analysis of safety, pharmacokinetic, and pharmacodynamic data;
- clinical trial design for combination therapies, including the standard approach involving randomization in studies with registrational intent;
- the need for further clinical data generation prior to defining a registration pathway.

Next Steps

Following the FDA meeting, the Management Board of the Company plans to undertake the steps required to initiate the dose expansion of romaciclib at 150 mg QD in the United States, including:

- updating the RIVER-81 study protocol, including clarification of safety criteria and the rationale for dose and regimen selection;
- submission of updated documentation to the FDA under the existing Investigational New Drug (IND) application, in line with the feedback received;
- initiation of patient enrollment in the U.S. expansion cohort following completion of the above regulatory steps.

After obtaining more mature clinical data from the expansion stage, the Company plans to hold a subsequent regulatory meeting with the FDA to discuss the further clinical development strategy for the romaciclib program in the aforementioned regulatory pathway.

Conclusion of a grant agreement with the National Centre for Research and Development

On March 11, 2026, the Company concluded a grant agreement (the "Agreement") with the National Centre for Research and Development (in Polish: Narodowe Centrum Badań i Rozwoju, "NCBR") for the co-financing of the Company's project entitled: "PERO - Predictive Engineering for Rational Oncology: functional mapping of therapeutic targets in oncology" ("Project"). The Agreement was concluded as a result of a call for proposals organized by the National Centre for Research and Development for entrepreneurs aimed at the development of critical technologies and technologies intended to protect and strengthen relevant critical technology value chains in the biotechnology sector under the European Funds for a Modern Economy Programme (FENG), Priority 5: Support for projects contributing to the objectives of the STEP initiative, FENG.05.01-IP.01-001/25 call - Track A: Projects implemented in the biotechnology sector.

The objective of PERO is to establish an innovative technological platform for the functional validation of structural protein pockets of potential therapeutic targets in oncology. The project addresses a significant technological gap by enabling an in-depth, currently unavailable level of functional target validation based on integrated genomic, structural, and pharmacological data.

- the total net value of the Project is: PLN 32,350,211.50;
- recommended amount of the funding: PLN 19,956,904.12;
- the planned duration of the Project: 51 months.

The funding granted under the Agreement will reduce the use of the Company's own funds.

Extension of the Research Collaboration Option and Exclusive License Agreement with BioNTech SE

On March 15, 2026, Ryvu and BioNTech SE, with its registered office in Mainz, Germany ("BioNTech"), entered into Amendment No. 1 to the research collaboration option and exclusive license agreement dated November 29, 2022 ("License Agreement"). The Company disclosed the conclusion of the License Agreement in its Current Report No. 26/2022 dated November 30, 2022.

Under the Amendment, the parties agreed, among others, to extend the term of the research collaboration conducted under the License Agreement by an additional period of one year, i.e., until November 29, 2028.
The remaining key terms of the License Agreement, including the economic terms of the collaboration and BioNTech's funding of discovery, research, and development activities thereunder, remain unchanged.

Poster presenting preclinical data for the ONCO Prime platform at the AACR Annual Meeting 2026

On April 20, 2026, during the AACR Annual Meeting held on April 17–22, 2026 in San Diego, California, the Company presented preclinical data for the ONCO Prime platform.

Details on the poster presentation are as follows:

Abstract Title: "ONCO Prime platform enables discovery of synthetic lethal targets for genetically stratified cancers"
Poster Number: 2989
Session date and time: 20/04/2026, 2:00 PM - 5:00 PM PDT

Colorectal cancer (CRC) remains a leading cause of cancer mortality, underscoring the need for new, mechanism-based therapeutic strategies. Using the ONCO Prime discovery and validation platform, based on genome-wide CRISPR/Cas9 screenings across clinically relevant models, we identified novel treatment options for genetically stratified CRC patients.

The ONCO Prime platform integrates healthy human intestinal stem cells (hISCs), isogenic CRC models carrying key driver mutations (*APC*, *KRAS*), and patient-derived primary cultures. All types of models can be genetically manipulated or used in the high-throughput setting for drug screening. Transcriptomic and machine learning analyses confirmed that these models faithfully recapitulate CRC molecular diversity and clinical behavior.

Systematic CRISPR/Cas9 loss-of-function screenings revealed multiple synthetic lethal (SL) interactions, uncovering target genes with first-in-class therapeutic potential. Additionally, using a clinical-grade drug that is FDA-approved in other indications, we achieved proof of concept in genetically stratified CRC models, demonstrating strong efficacy as monotherapy in vitro. These data validate ONCO Prime's translational capability to uncover clinically actionable vulnerabilities and deliver tangible therapeutic candidates.

This work provides a robust foundation for drug discovery programs and strategic partnerships built on ONCO Prime's ability to bridge functional genomics with therapeutic development. Our first proof of concept establishes ONCO Prime as a scalable platform to drive the next generation of precision, first-in-class oncology therapies.

The poster is now available online and can be obtained from the conference site: https://www.aacr.org/

Romaciclib development priorities update

On May 20, 2026, the Company announced development and financing priorities for romaciclib (RVU120).

Following an analysis of Company resources and clinical data generated so far, the Management Board of the Company decided to prioritize romaciclib's development in acute myeloid leukemia (AML), particularly in patients with relapsed/refractory AML following venetoclax-based regimens, which represents the area of greatest unmet medical need and the most compelling clinical data observed to date.

This approach is intended to preserve strategic optionality for romaciclib while, in the short term, focusing resources on the clinical dataset expected to be most relevant to potential development partners for romaciclib.

Current discussions with interested parties indicate that the optimal timing for a partnering transaction will follow the completion of the dose expansion in the RIVER-81 study with the 150 mg QD cohort. Accordingly, the Company plans to continue the RIVER-81 study by enrolling approximately 30 additional patients subject to regulatory clearances.

As part of resource prioritization, the Management Board of the Company decided to close the POTAMI-61 Phase II study investigating romaciclib for the treatment of patients with intermediate- or high-risk primary or secondary myelofibrosis (MF). Romaciclib demonstrated a favorable safety profile and clinical activity in MF, both as monotherapy and in combination with ruxolitinib. The observed spleen volume reductions and hematologic tolerability support continued clinical evaluation.

POTAMI-61 was initiated on December 4, 2024, as the Company informed in the Current Report ESPI 37/2024 dated December 5, 2024. Following completion of Part A (23 patients) and initial enrollment in Part B (5 patients), the Company has decided not to proceed with further enrollment, closing the study at 28 patients. Patients currently participating in the study and deriving clinical benefit from romaciclib according to the investigators' assessment will continue to receive treatment in a new rollover study (ROVER-01), in accordance with applicable regulatory and ethical requirements. The Company will analyze data from POTAMI-61 to inform potential future MF development decisions and retains the option to resume a modified MF development program.

Based on currently available information and existing development plans, the above decisions are not expected to have a material adverse impact on the Company's 2026 and 2027 financial outlook.

Clinical data on romaciclib presented at the 2026 European Hematology Association Congress

The Company presented clinical data on romaciclib (RVU120) at the European Hematology Association Congress (EHA), June 11-14, 2026, in Stockholm, Sweden.

Program updates:

In the RIVER-81 trial of patients with r/r AML, Ryvu is initiating an expansion cohort of approximately 30 patients to confirm the positive efficacy demonstrated in the dose cohort of 150 mg QD romaciclib combined with 400 mg QD venetoclax, as the Company informed in the current report no. 9/2026 dated May 20, 2026. Following completion of the required regulatory steps,

including an updated study protocol and submission of documentation under the existing IND, the FDA reactivated the IND for the RIVER-81 study on May 28, 2026.

In the POTAMI-61 study investigating romaciclib's efficacy in MF, eight patients will be transferred into the ROVER-01 study rollover protocol, underscoring that a subset of patients continue to derive meaningful clinical benefit from romaciclib treatment. These patients will continue to receive treatment with romaciclib as long as they benefit in ROVER-01.

EHA poster presentations:

Poster (PF521): Updated findings from the Phase 2 **RIVER-81** study of romaciclib (RVU120) combined with venetoclax in acute myeloid leukemia after first-line venetoclax and hypomethylating agent failure

Poster session date and time: Friday, June 12 (6:45 - 7:45 PM CEST)

Venetoclax (VEN) combined with hypomethylating agents is the standard first-line treatment for patients with acute myeloid leukemia (AML) ineligible for intensive chemotherapy, yet ~70% experience relapsed/refractory disease with a median survival of under three months. Romaciclib, a first-in-class CDK8/CDK19 inhibitor, has shown single-agent activity in AML and preclinical synergy with VEN through enhanced apoptotic signaling and attenuation of resistance pathways.

In the ongoing Phase 2 RIVER-81 trial, romaciclib in combination with VEN demonstrates anti-leukemic activity in patients with poor prognostic AML. While responses have been observed across dose levels, the most consistent responses were seen at romaciclib 150 mg QD + VEN 400 mg QD, including two complete remissions with (CR) and one without (CRi) full hematologic recovery, resulting in a CR/CRi rate of 43% (3/7). The mean duration of response (DoR) of the CRs was 156 days, reported with a cut-off date of 12 May 2026. Based on safety, PK, and preliminary efficacy findings, this regimen was selected as the recommended dose for expansion.

Poster (PS2008): Romaciclib (RVU120), a selective CDK8/19 inhibitor, as monotherapy or in combination with ruxolitinib in patients with myelofibrosis: Updated results from the phase II **POTAMI-61** study

Poster session date and time: Saturday, June 13 (6:45 - 7:45 PM CEST)

Myelofibrosis (MF) is driven by dysregulated JAK/STAT signaling, and while JAK inhibition with ruxolitinib (RUX) improves splenomegaly and symptoms, cytopenias and suboptimal responses remain clinical challenges. Romaciclib is a first-in-class, oral CDK8/19 inhibitor that modulates STAT-dependent transcription and shows synergy with RUX in preclinical MF models.

In the ongoing Phase II POTAMI-61 study, romaciclib administered as monotherapy or combined with RUX demonstrates a manageable safety profile in patients with MF without significant treatment-related cytopenias. Prolonged exposure, spleen volume reductions, including in patients with high-molecular-risk mutations, and favorable hematologic tolerability support continued clinical development.

The posters are available online and can be accessed via the conference website: https://ehaweb.org/ and Ryvu's website: https://ryvu.com/

Appointment of Supervisory Board Members of Ryvu Therapeutics S.A. for a new term of office

The Ordinary General Meeting of the Company has appointed, effective June 25, 2026, the Supervisory Board Members of the Company for a new term of office, in the following composition:
1. Mr. Piotr Romanowski - Chairman of the Supervisory Board of the Company;
2. Mr. Tadeusz Wesołowski – Vice-Chairman of the Supervisory Board of the Company;
3. Mr. Rafał Chwast - Member of the Supervisory Board of the Company;
4. Mr. Scott Z. Fields - Member of the Supervisory Board of the Company;
5. Mr. Peter Smith - Member of the Supervisory Board of the Company.

Appointment of Management Board Members of Ryvu Therapeutics S.A. for a new term of office

The Supervisory Board of the Company has appointed, effective June 25, 2026, the Management Board Members of the Company for a new 5-year term of office in the following composition:
1. Mr. Paweł Przewięźlikowski - President of the Management Board;
2. Mr. Krzysztof Brzózka - Vice-President of the Management Board;
3. Mr. Kamil Sitarz - Vice-President of the Management Board;
4. Mr. Hendrik Nogai - Member of the Management Board;
5. Ms. Justyna Żółtek - Member of the Management Board.

Conclusion of an amendment to the global license agreement with Menarini Group concerning the further clinical development of dapolsertib

On July 22, 2026, the Company concluded with Berlin-Chemie AG, with its registered office in Berlin, Germany, a member of the Menarini Group (the "Menarini Group"), an amendment (the "Amendment") to the global license agreement concerning dapolsertib, also known as MEN1703 and SEL24 (the "Agreement").
Pursuant to the Amendment, Menarini Group will expand the clinical development of dapolsertib by initiating a new Phase II clinical study in patients with myelofibrosis, a rare hematological malignancy. The study will evaluate dapolsertib primarily as monotherapy. The decision to initiate the study is supported by preclinical data indicating activity of dapolsertib in myelofibrosis models.
The Company will act as sponsor of the study and will be responsible for its operational conduct on behalf of Menarini Group, including, in particular, study management, clinical monitoring, regulatory submissions, medical oversight and data management. Menarini Group will be responsible for funding all study activities covered by the Amendment in accordance with the agreed budgets, and the Company will receive full reimbursement of costs incurred in connection with the conduct of the study, in line with those budgets.

Dapolsertib is a selective, small-molecule, dual inhibitor of PIM and FLT3 kinases, two enzymes strongly implicated in the malignant transformation of hematopoietic cells. The compound has been discovered by the Company and is currently in clinical development in collaboration with Menarini, which holds global development and commercial rights to dapolsertib.

The conclusion of the Amendment is material for the further clinical development of the dapolsertib program, as it expands the program into a new indication and defines the further scope of the Company's operational collaboration with Menarini Group.

Ryvu launches a specialized early clinical development services business under the "Keelira" brand

On August 18, 2026, the Company launched a specialized early clinical development services business providing biotech and pharma companies with integrated services supporting the development of oncology programs across European markets.

The Company will provide these services under the dedicated “Keelira” brand, from preparation of programs for clinical entry through Phase I and Phase II development, with a particular focus on oncology, hemato-oncology and rare oncology indications. Keelira’s service model combines Clinical Execution, Strategic Advisory and Central Lab services.

Keelira’s operating model was developed within the Company to support the development of its own oncology pipeline and was subsequently applied in clinical collaborations with external international biotech and pharma companies. The purpose of launching Keelira is to commercialize the Company’s existing clinical development capabilities and to develop a complementary revenue stream in a capital-efficient manner.

The Keelira services business has been designed to develop alongside the Company’s core drug discovery and development activities. Accordingly, Keelira operates within Ryvu under a dedicated operating model and quality management system, with separate data-management arrangements and governance rules applicable to external clients. The development of the Company’s own oncology pipeline remains its strategic priority.

The Keelira services business will be led by Kamil Sitarz, Vice-President of the Management Board and Chief Operating Officer of Ryvu Therapeutics, who will serve as General Manager of Keelira.

Recommendation of Ryvu’s project for funding by the Polish Agency for Enterprise Development

On September 7, 2026, the Company's project titled “DUALIS - technology platform for the discovery of next-generation bivalent ADC payloads” ("Project") was placed on the ranked list of projects recommended for funding under the SMART Path call for entrepreneurs, organized by the Polish Agency for Enterprise Development ("PARP"). The call is implemented under the European Funds for a Modern Economy Programme (FENG), Priority 1: “Support for Entrepreneurs”, FENG.01.01-IP.02-001/26 call.

The objective of DUALIS is to develop and implement an innovative DUALIS technology platform designed to accelerate and increase the efficiency of the discovery of next-generation bivalent payloads used in antibody-drug conjugates (ADC) in oncology. The platform is intended to enable the generation of new classes of payloads with complex, synergistic mechanisms of action, including those based on the simultaneous modulation of two biological targets and induced proximity mechanisms within a novel discovery process, thereby addressing significant limitations of currently used ADC technologies.

- the total net value of the Project is: PLN 30,860,980.64;
- recommended amount of the funding: PLN 22,245,183.62;
- the planned duration of the Project: 54 months.

Conclusion of a grant agreement with the National Centre for Research and Development

On September 18th, 2026, the Company concluded a grant agreement (the “Agreement”) with the National Centre for Research and Development (in Polish: Narodowe Centrum Badań i Rozwoju, “NCBR”) for the co-financing of the Company’s project entitled: “PANACEA-NOVO - patient-oriented innovative targeted therapies for rare cancers”. The Agreement was concluded following FENG.05.01-IP.01-001/26 call for proposals - “Projects of Polish enterprises designated as associated partners in the European Commission’s decision on IPCEI in an area relevant to the implementation of the STEP

initiative", under the European Funds for a Modern Economy Programme (FENG), Priority 5 - Support for projects contributing to the objectives of the STEP initiative.

The objective of the PANACEA-NOVO project is to develop a unique technology platform for the discovery and validation of novel therapeutic targets with potential applications in the treatment of rare cancers for which effective, targeted treatment options are currently lacking. The platform will establish an integrated workflow from the oncology patient to the biological target and subsequently to the development of a targeted therapy.
- the total net value of the Project is: PLN 133,186,597.38;
- recommended amount of the funding: PLN 105,624,275.09;
- the planned duration of the Project: 58 months.

The funding granted under the Agreement will reduce the use of the Company's own funds.

2.2.2. Events that occurred between the end of the reporting period and the approval of the financial statements

Preclinical in vivo data for RVU602, a novel ADC payload, presented at the World ADC Congress 2026

On October 14, 2026, the Company presented preclinical data, including in vivo proof-of-concept data, on antibody-drug conjugates (ADCs) based on RVU602 – its proprietary, potentially first-in-class ADC payload – at the World ADC Congress 2026, held on October 12-15, 2026, in San Diego, CA, USA.

Details of the poster presentation:

Poster No. 96: RVU602: A Non-TOPO1/Non-Tubulin Payload for Next-Generation ADCs
Session date and time: October 14, 2026, 10:00 AM PDT (7:00 PM CEST)
What differentiates the RVU602 payload

- **A third mechanistic class.** Transcriptomic profiling shows that RVU602 induces neither the replication-stress signature characteristic of TOPO1 inhibitors nor the mitotic-arrest signature of tubulin inhibitors. This opens the option of sequencing RVU602-based ADCs after, or combining them with, DXd- and MMAE-based ADCs.
- **Active in TOPO1 inhibitor-resistant tumors.** In cells carrying a TOPO1 mutation, deruxtecan (DXd) lost more than 100-fold potency, whereas RVU602 retained full activity (resistant/parental EC50 ratio of 1.0-4.4). This is directly relevant for the growing population of patients progressing on TOPO1 inhibitor-based ADCs.
- **No efflux liability.** In a P-gp-high cell line, RVU602 potency was essentially unaffected by P-gp inhibition (1.6-fold shift, versus 3.7-fold for DXd and 12-fold for MMAE), indicating that RVU602 overcomes a major efflux-driven resistance route.
- **Built-in immunomodulatory activity.** Beyond direct cytotoxicity, RVU602 induces the release of extracellular ATP, a hallmark of immunogenic cell death, supporting the potential of RVU602-based ADCs in combination with immune checkpoint blockade.
- **Deep, pan-tumor cytotoxicity.** Across a panel of 272 cancer cell lines, RVU602 showed broad cytotoxic activity and a markedly deeper response than DXd.

ADC validation and in vivo proof of concept

- RVU602 was conjugated to four antibodies – sacituzumab (anti-TROP2), cetuximab (anti-EGFR), telisotuzumab (anti-c-MET) and trastuzumab (anti-HER2). The resulting ADCs showed high monomeric content (>95%), high drug-to-antibody ratios (DAR 6-8) and low payload release in plasma (<1% in mouse and <15% in human plasma after 7 days).
- RVU602 ADCs combined sub-nanomolar potency with complete tumor cell killing in vitro, outperforming datopotamab deruxtecan (Dato-DXd) and matching a cetuximab-MMAE comparator.
- In patient-derived TROP2-positive TNBC cells, the RVU602 ADC achieved low-nanomolar potency (EC50 0.4-7.5 nM) with 100% efficacy and 30- to 250-fold selectivity over the isotype control, supporting its translational potential.
- In the TROP2-positive HCC70 TNBC xenograft model, the sacituzumab-RVU602 ADC led to complete responses in 100% of animals after two doses at 10 mg/kg once weekly (QW) and in 83% of animals after four doses at 5 mg/kg twice weekly (BIW). Strong target engagement in tumors correlated with tumor growth inhibition. Sacituzumab govitecan (20 mg/kg QW) was included as a reference arm.

Together, these data validate RVU602 across multiple antibody targets and models, including settings resistant to topoisomerase I inhibitors, and support RVU602 as a differentiated payload for next-generation ADCs.

Preclinical data on RVU602, a novel ADC payload, and the ONCO Prime platform to be presented at the 2026 EORTC-NCI-AACR Symposium

The Company will present two posters with preclinical data on RVU602, its proprietary novel ADC payload, and on the ONCO Prime platform at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA), November 18-20, 2026, Barcelona, Spain.

Details on the poster presentations are as follows:

Abstract Title: RVU602: A Non-TOP1/Non-Tubulin Cytotoxic and Immunomodulatory Payload for Next-Generation ADCs
Abstract Number: 72
Session date and time: Wednesday, November 18 (09:00-17:00 CET)
RVU602 is a proprietary, potentially first-in-class ADC payload. Its mechanism of action is distinct from both topoisomerase I (TOPO1) inhibitors and microtubule inhibitors, the two payload classes on which nearly all approved and late-stage ADCs rely. RVU602 was discovered on Ryvu's payload discovery platform, which integrates patient-derived models and high-throughput phenotypic screening. RVU602 disrupts an essential intracellular survival process. It shows broad activity across cancer cell states, including those less responsive to classical payloads. In a subset of cell lines, it showed higher potency than DXd (mean EC50 of 34 nM vs. 45 nM).
RVU602 was conjugated to four antibodies: sacituzumab (anti-TROP2), cetuximab (anti-EGFR), telisotuzumab (anti-c-MET) and trastuzumab (anti-HER2). It formed active ADCs with all of them, reaching sub- to low-nanomolar potency (EC50 of 0.22-14 nM in TROP2-responsive models), a 3- to 23-fold shift versus the free payload. In TROP2 models, the sacituzumab-RVU602 ADC matched or

exceeded datopotamab deruxtecan (Dato-DXd). The cetuximab-RVU602 ADC was on par with a cetuximab-MMAE comparator. The sacituzumab-RVU602 ADC was efficacious and well tolerated in the TROP2-positive HCC70 xenograft model.
Beyond direct cytotoxicity, RVU602 induces the release of extracellular ATP, a hallmark of immunogenic cell death, exceeding the effect of a topoisomerase inhibitor. Together, these data confirm the activity of RVU602 across multiple antibodies and in settings resistant to TOPO1 inhibitors. Validation of tolerability and therapeutic window is ongoing.

Abstract Title: Mapping Hidden Vulnerabilities in Genetically Stratified Colorectal Cancer with ONCO Prime
Abstract Number: 195
Session date and time: Thursday, November 19 (09:00-17:00 CET)

Ryvu has developed a proprietary platform, ONCO Prime, to identify actionable vulnerabilities in genetically defined cancer contexts. The platform combines clinically relevant model systems, including healthy human intestinal stem cells (hISCs), engineered isogenic colorectal cancer (CRC) models carrying key oncogenic drivers such as APC and KRAS alterations, and patient-derived cells (PDCs). These models are amenable to genetic perturbation and high-throughput pharmacological testing. Molecular profiling, transcriptomic analyses and computational approaches further support patient stratification and link functional phenotypes with pathway states.
Using genome-wide CRISPR/Cas9 loss-of-function screening followed by orthogonal validation in patient-derived CRC models, the team identified multiple synthetic lethal (SL) interactions associated with WNT and RAS/MAPK pathway dysregulation. The platform enabled prioritization of novel targets with first-in-class therapeutic potential. It also revealed opportunities for drug repurposing of clinically advanced or approved agents. In genetically stratified CRC models, selected pharmacological interventions demonstrated robust in vitro activity, including context-dependent responses and combination potential.

Together, these findings demonstrate that ONCO Prime can systematically connect cancer genotype, pathway activity and functional vulnerability to nominate therapeutically relevant targets. This supports the development of both first-in-class programs and repositioning strategies for defined CRC patient populations.

First clinical data from the Phase II JASPIS-01 study of dapolsertib (MEN1703, SEL24) and initial data from the expansion cohort of the Phase II RIVER-81 study of romaciclib (RVU120) in combination with venetoclax to be presented at the 2026 ASH Annual Meeting

On November 4, 2026, the Company announced that the first clinical data from the ongoing Phase II JASPIS-01 study (NCT06534437) of dapolsertib (MEN1703, SEL24) in patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL), as well as the initial data from the expansion cohort of the ongoing Phase II RIVER-81 study (NCT06191263) of romaciclib (RVU120) in combination with venetoclax, will be presented in poster sessions at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, held December 12-15, 2026, in New Orleans, Louisiana, USA, and virtually.

Phase II JASPIS-01 study of dapolsertib (MEN1703, SEL24):

Dapolsertib is a first-in-class, oral, selective small-molecule dual inhibitor of PIM and FLT3 kinases, discovered by Ryvu. Global development and commercial rights to dapolsertib are licensed to the Menarini Group ("Menarini"). Since September 2023, Ryvu has been Menarini's operational partner for Phase II study execution, with Menarini funding all research and development costs.

The abstract published on November 4, 2026 reports the first clinical results from Group 2 of the JASPIS-01 study, which evaluates dapolsertib monotherapy in adults with R/R aggressive B-NHL who have exhausted available standard treatment options following at least two prior systemic therapies. The data cutoff date was June 18, 2026. Enrollment in the study is ongoing.

Clinical activity was observed in a heavily pretreated population, with a median of four prior lines of therapy; 53% of patients had previously received CAR-T cell therapy and 60% had received CD3×CD20 bispecific antibodies. At the data cutoff, 15 patients had received dapolsertib monotherapy, and clinical benefit was observed in 4 of them despite extensive prior therapy, including one complete response. The safety profile was manageable and no new signal was observed. These initial findings support the continued clinical development of dapolsertib in aggressive B-cell lymphoma.

The poster to be presented at ASH 2026 may include additional and updated information.

Details on the poster presentation are as follows:

Poster Title: Preliminary clinical activity and safety of dapolsertib (MEN1703), a first-in-class dual PIM/FLT3 inhibitor, in heavily pretreated relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: Initial results from the Phase II JASPIS-01 trial

Publication Number: 3662

Session: 627. Aggressive Lymphomas: Targeted and Pharmacologic Therapies: Poster II

Session date and time: Sunday, December 13, 2026, 6:00-8:00 PM CST (1:00-3:00 AM CET on December 14)

Location: Ernest N. Morial Convention Center, Hall F, New Orleans, Louisiana

Phase II RIVER-81 study of romaciclib (RVU120) in combination with venetoclax:

Venetoclax (VEN) in combination with a hypomethylating agent (HMA) is the standard of care for older or unfit patients with acute myeloid leukemia (AML); however, most patients relapse, and outcomes after failure of VEN-based therapy remain poor. Romaciclib (RVU120) is a first-in-class, selective CDK8/CDK19 inhibitor with single-agent activity in AML, discovered and fully owned by Ryvu. The RIVER-81 study evaluates romaciclib in combination with VEN in patients with AML after failure of frontline VEN+HMA therapy.

The abstract published on November 4, 2026 contains data as of the July 1, 2026 cutoff date, i.e. prior to the initiation of the expansion cohort on August 26, 2026, and does not provide any significant update compared with the data presented in the poster at the 2026 European Hematology Association (EHA) Congress, as reported by the Company in current report No. 12/2026 of June 11, 2026.

The poster to be presented at ASH 2026 will include additional and updated information.

Details on the poster presentation are as follows:

Poster Title: Phase II RIVER-81 updated Results: Romaciclib plus venetoclax after first-line venetoclax and hypomethylating-agent failure in adults with relapsed or refractory acute myeloid leukemia

Publication Number: 5153

Session: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster III

Session date and time: Monday, December 14, 2026, 6:00-8:00 PM CST (1:00-3:00 AM CET on December 15)

Location: Ernest N. Morial Convention Center, Hall F, New Orleans, Louisiana

The abstracts are now available online and can be obtained from the conference site: https://www.hematology.org/Meetings/Annual-Meeting/Abstracts

The posters will be available on the Company's website after the presentations: https://ryvu.com/investors-media/publications/

2.3. Unusual events occurring in the reporting period

Not applicable.

3. THE ISSUER'S CORPORATE BODIES

Issuer's Management Board:

1) Paweł Przewięźlikowski – President of the Management Board
2) Krzysztof Brzózka – Vice-President of the Management Board
3) Kamil Sitarz – Vice-President of the Management Board
4) Vatnak Vat-Ho – Member of the Management Board until June 25, 2026.
5) Hendrik Nogai – Member of the Management Board
6) Justyna Żółtek – Member of the Management Board

Issuer's Supervisory Board:

1) Piotr Romanowski – Chairman of the Supervisory Board
2) Tadeusz Wesołowski – Vice-Chairman of the Supervisory Board
3) Rafał Chwast – Supervisory Board Member
4) Axel Glasmacher – Supervisory Board Member until June 25, 2026.
5) Thomas Turalski – Supervisory Board Member until June 25, 2026.
6) Scott Z. Fields – Supervisory Board Member
7) Peter Smith – Supervisory Board Member

Issuer's Audit Committee:

1) Rafał Chwast – Chairman of the Audit Committee
2) Piotr Romanowski – Member of the Audit Committee
3) Tadeusz Wesołowski – Member of the Audit Committee

The Company's Remuneration Committee:

1) Piotr Romanowski – Chairman of the Remuneration Committee until June 25, 2026 and from July 14, 2026
2) Axel Glasmacher – Member of the Remuneration Committee until June 25, 2026
3) Thomas Turalski – Member of the Remuneration Committee until June 25, 2026
4) Scott Z. Fields – Member of the Remuneration Committee from July 14, 2026
5) Peter Smith - Member of the Remuneration Committee from July 14, 2026

4. INFORMATION ON THE SHAREHOLDERS HOLDING (DIRECTLY OR INDIRECTLY) AT LEAST 5% OF THE TOTAL NUMBER OF VOTES AT THE GENERAL SHAREHOLDERS' MEETING OF THE COMPANY AND ON SHARES HELD BY MEMBERS OF THE ISSUER'S MANAGEMENT BOARD AND SUPERVISORY BOARD

Shares held by members of the Management and Supervisory Board of Ryvu Therapeutics S.A. as of 30.09.2026 and as of the date of Report publication

Shareholder	Preferred shares*	Ordinary shares	Number of shares	% of Share Capital	Number of Votes	% of Votes at SM
The Management Board						
Paweł Przewięźlikowski (through Benevora Fundacja Rodzinna w organizacji)**	3 500 000	482 160	**3 982 160**	17.22%	**7 482 160**	27.54%
Krzysztof Brzózka		267 321	**267 321**	1.16%	**267 321**	0.98%
Kamil Sitarz		39 230	**39 230**	0.17%	**39 230**	0.14%
Hendrik Nogai		22 500	**22 500**	0.10%	**22 500**	0.08%
Justyna Żółtek		18 265	**18 265**	0.08%	**18 265**	0.07%
The Supervisory Board						
Tadeusz Wesołowski (directly)		92 975	**92 975**	0.40%	**92 975**	0.34%
Tadeusz Wesołowski* (indirectly through Fundacja Rodzinna Rodziny Wesołowskich Fundacja Rodzinna w Krakowie)**		1 279 738	**1 279 738**	5.54%	**1 279 738**	4.71%
Rafał Chwast		121 115	**121 115**	0.52%	**121 115**	0.45%

**A single Series A share entitles its holder to two votes at the Shareholder Meeting.*

***A beneficiary of Benevora Fundacja Rodzinna w organizacji is Mr. Paweł Przewięźlikowski – President of the Management Board*

****The beneficiary of Fundacja Rodzinna Rodziny Wesołowskich Fundacja Rodzinna w Krakowie is Mr. Tadeusz Wesołowski - Vice-Chairman of the Supervisory Board.*

Shares held by significant shareholders of the Company

Shares held by significant shareholders of the Company as of 30.09.2026 and as of the date of Report publication

Shareholder	Shares	% [Shares]	Votes	% [Votes]

Paweł Przewięźlikowski (through Benevora Fundacja Rodzinna w organizacji)*	3 982 160	17.22%	7 482 160	27.54%
Bogusław Sieczkowski (through CapitalS Fundacja Rodzinna w organizacji)**	825 348	3.57%	1 375 348	5.06%
Tadeusz Wesołowski (with Fundacja Rodzinna Rodziny Wesołowskich Fundacja Rodzinna w Krakowie)***	1 372 713	5.94%	1 372 713	5.05%
Nationale Nederlanden OFE	1 385 262	5.99%	1 385 262	5.10%
Allianz Polska OFE	2 292 540	9.92%	2 292 540	8.44%
BioNTech SE	1 917 437	8.29%	1 917 437	7.06%

** A beneficiary of Benevora Fundacja Rodzinna w organizacji is Mr. Paweł Przewięźlikowski*

***A beneficiary of CapitalS Fundacja Rodzinna w organizacji is Mr. Bogusław Sieczkowski*

****The beneficiary of Fundacja Rodzinna Rodziny Wesołowskich Fundacja Rodzinna w Krakowie is Mr. Tadeusz Wesołowski*

The above information on the state of possession of the Issuer's shares by shareholders (including those being members of the Company's bodies) holding directly and indirectly at least 5% of the total number of votes at the Company's General Meeting has been prepared on the basis of information obtained from shareholders through their performance of duties imposed on shareholders of public companies by virtue of relevant legal regulations, including on the basis of the provisions of the Act of 29 July 2005 on public offering and the conditions for introducing financial instruments to the organized trading system and on public companies (art. 69 and art. 69a) and on the basis of the provisions of the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC (MAR Regulation, art. 19). In addition, information on the ownership of the Company's shares is provided on the basis of publicly available data on the portfolio exposure and asset structure of investment funds or pension funds, including information on the number of shares registered at the Company's General Meeting (data available periodically, inter alia, based on information from the financial statements of investment funds and pension funds - data may be subject to change since the date of publication of the last information).

5. STATEMENT OF THE MANAGEMENT BOARD REGARDING APPLICABLE ACCOUNTING PRINCIPLES

The management board of Ryvu Therapeutics S.A. confirms that, to the best of its knowledge, these quarterly financial statements of Ryvu Therapeutics S.A. and comparative data have been prepared in accordance with the applicable accounting principles and reflect in a true, fair and clear manner the Company's property and financial position and its financial result.

The report of the management board on the activities of Ryvu Therapeutics S.A. contains a true picture of the development, achievements and situation of the Company, including a description of the main threats and risks.

6. ADDITIONAL INFORMATION

Proceedings pending at court, before an arbitration institution or a public administration authority

The Company has filed a lawsuit against DUNA POLSKA S.A. (formerly: Mota-Engil Central Europe S.A.) ("Contractor") to the District Court in Kraków concerning the construction of the Research and Development Center under the agreement for "Construction of the Research and Development Center of Innovative Drugs Selvita S.A." dated August 13, 2018 ("Construction Agreement"). The claims include payment of contractual penalties for failure to meet the final and intermediate deadlines, as well as for untimely rectification of defects related to the scope of the Construction Agreement, totalling PLN 13,756,717.07. The total value of the Construction Agreement was PLN 68,783,585.34, including VAT. The proceedings are taking place before the District Court in Kraków in the first instance. On July 8, 2024, the Court concluded the oral hearings of the witnesses and the Parties, simultaneously requiring the Parties to pay advances toward the expert's opinion (by July 22, 2024) and to inform the Court of the mutually agreed-upon candidates for experts (by September 1, 2024). The Parties responded to the Court's request within the above-mentioned deadlines. Subsequently, the Court requested the Parties to take a position on the offer of the expert selected by the Parties, who will prepare an opinion within the scope of the evidence outlined by the Parties. Both Parties accepted the offer. The files have been sent to an expert who will prepare an opinion based on the questions outlined by the Parties. The court has extended the deadline for preparing the opinion to July 30, 2026. As of the date of publication of the report, the opinion had not been submitted. The court imposed a fine on the expert witness for the delay in submitting his opinion. The Company has filed with the case file a supplementary opinion issued in case no. IX GC 967/21, together with the objections drawn up in response to it.

The Contractor has filed a lawsuit for payment against the Company to the District Court in Kraków in connection with the performance of the Construction Agreement for the project entitled: "Construction of the Research and Development Center for Innovative Drugs Selvita S.A." In the lawsuit, the Contractor is claiming damages for the costs incurred in connection with prolonged performance of the Construction Agreement, the unpaid portion of the lump sum fee as well as supplementary remuneration for additional, replacement and omitted works (PLN 5,391,425.63) as well as reimbursement of the amount resulting from the Company's unauthorized - in the Contractor's opinion - application of the performance bond and removal of the defects and faults (PLN 2,063,507.56). Including statutory interest, the Contractor demands a total amount of PLN 7,671,285 from the Company. On November 22, 2023, the hearings of all witnesses and parties were completed. Subsequently, the files were forwarded to a court expert for the preparation of an opinion. On April 8, 2025, the expert's opinion was delivered to the Company, to which the Parties submitted objections in a procedural letter dated May 30, 2025. The expert responded to the objections and submitted an offer to prepare a supplementary opinion. The expert has now submitted a supplementary opinion, to which both parties have raised objections. At the same time, the Company has appealed against the court's order awarding the expert additional remuneration for drawing up the supplementary opinion.

Significant non-arm's length transactions with related entities

Not applicable.

Information on organizational or capital relations of the Issuer with other entities

As of the report's publication date, the Issuer does not form a Capital Group. As at the date of this Report, the Issuer holds 1.06% of shares in Rezera Inc. (formerly NodThera Inc.).

Warranties for loans and borrowings and guarantees granted

Not applicable.

Other information significant for the assessment of the Issuer's position in the area of human resources, assets, cash flows, financial results and changes thereof and information significant for the assessment of the Issuer's ability to settle its liabilities

Not applicable.

Factors which, in the Issuer's opinion, will affect the results over at least the following quarter

The results of the subsequent quarters will depend primarily on the execution of the Company's strategy, which assumes in particular that the following business objectives will be met:

- Advancing romaciclib (RVU120) through Phase II clinical development in relapsed/refractory AML following failure of venetoclax-based regimens — an indication with significant unmet medical need and no approved standard of care — with the objective of generating the clinical data required to define a registration pathway and support potential partnering transactions; the Company continues to evaluate options for future romaciclib development in additional hematologic indications based on emerging data;
- Supporting clinical development of its partnered candidate, dapolsertib (MEN1703, SEL24) by Menarini Group;
- Strengthening the Company's discovery pipeline and accelerating progress using a first-in-class, novel small-molecule precision medicine approach via its proprietary ONCO Prime platform, as well as antibody-drug conjugates (ADCs) with novel payloads;
- Achieving financial milestones in the existing R&D collaborations (i.e. BioNTech, Exelixis, Menarini);
- Growing Keelira, the Company's dedicated early clinical development services business launched in August 2026, by expanding its client portfolio, with the objective of establishing it as a capital-efficient, complementary revenue stream alongside the Company's own oncology pipeline;
- Advancing business development activities for fully owned programs, including romaciclib, involving structured discussions with potential partners regarding licensing, co-development, and option arrangements across multiple markets, with the objective of concluding a partnering transaction upon achievement of pre-specified clinical data milestones from the RIVER-81 expansion cohort.

Explanations regarding the seasonal or cyclical nature of the Issuer's operations in the reported period

Not applicable.

Information on inventory write-downs to the net realizable amount and reversal of such write-downs

Not applicable.

Information on impairment write-downs in respect of financial assets, tangible fixed assets, intangible assets or other assets and the reversal of such write-downs

Not applicable.

Information on the set-up, increase, utilization and reversal of provisions

Information on the changes in provisions for holidays and bonuses is provided in note 17 to the financial statements.

Information on deferred income tax provisions and assets

No significant changes.

Information on significant purchases or disposals of tangible fixed assets

No significant changes.

Information on significant liabilities in respect of purchases of tangible fixed assets

No significant changes.

Information on significant settlements resulting from court cases

Not applicable.

Error corrections relating to previous periods

Not applicable.

Information on changes in the economic situation and business conditions, which have a significant effect on the fair value of the entity's financial assets and financial liabilities

Not applicable.

Information on the failure to repay a loan or borrowing or a breach of significant terms and conditions of a loan agreement, with respect to which no corrective action had been taken by the end of the reporting period

Not applicable.

Information on changes in the method of valuation of financial instruments measured at the fair value

Not applicable.

Information on changes in the classification of financial assets due to a change in their purpose

Not applicable.

Information on the issue, redemption and repayment of non-equity and equity securities

Not applicable.

Information on dividends paid (or declared) in the total amount and per share, divided into ordinary and preference shares

Not applicable.

Events that occurred after the date for which the quarterly financial statements were prepared, not disclosed in these financial statements although they may have a significant effect on the Issuer's future financial results

Not applicable.

Information on changes in contingent liabilities or contingent assets that occurred after the end of the last financial year

Information on changes in contingent liabilities or contingent assets is provided in note 22 to the financial statements.

Other disclosures which may have a material impact on the assessment of the Issuer's financial position and results of operations

Not applicable.

Amounts and types of items affecting the assets, liabilities, equity, net profit/ (loss) or cash flows, which are unusual in terms of type, amount or frequency

Not applicable.

Kraków, November 18, 2026

Dokument podpisany przez Paweł Tadeusz Przewięźlikowski
Data: 2026.11.18 11:26:57 CET

Paweł Przewięźlikowski
President of the Management Board

Dokument podpisany przez Krzysztof Daniel Brzózka
Data: 2026.11.18 10:56:32 CET

Krzysztof Brzózka
Vice-President of the Management Board

Dokument podpisany przez Kamil Sebastian Sitarz
Data: 2026.11.18 10:43:46 CET

Kamil Sitarz
Vice-President of the Management Board

Signed by / Podpisano przez:
FRANZ HENDRIK DR. NOGAI
Date / Data: 2026-11-18 12:36

Hendrik Nogai
Management Board Member

Elektronicznie podpisany przez Justyna Katarzyna Żółtek
Data: 2026.11.18 12:05:05 +01'00'

Justyna Żółtek
Management Board Member

CONTACT

RYVU THERAPEUTICS

2 Sternbacha Street

30-394 Krakow, Poland

P: +48 12 314 02 00

GENERAL INQUIRIES

ryvu@ryvu.com

RYVU THERAPEUTICS